Korea Investment CORP Sells 5,447 Shares of Humana Inc. $HUM

Korea Investment CORP lowered its holdings in Humana Inc. (NYSE:HUM) by 6.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 73,416 shares of the insurance provider’s stock after selling 5,447 shares during the period. Korea Investment CORP owned about 0.06% of Humana worth $17,949,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in HUM. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Humana by 16.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider’s stock worth $300,728,000 after purchasing an additional 158,528 shares during the period. Focus Partners Wealth grew its position in Humana by 104.2% during the first quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider’s stock worth $1,701,000 after buying an additional 3,281 shares in the last quarter. Swedbank AB grew its position in Humana by 5.3% during the second quarter. Swedbank AB now owns 100,397 shares of the insurance provider’s stock worth $24,545,000 after buying an additional 5,032 shares in the last quarter. Circle Wealth Management LLC bought a new position in Humana in the 1st quarter worth about $425,000. Finally, Kera Capital Partners Inc. purchased a new stake in shares of Humana in the 2nd quarter valued at about $253,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

HUM stock opened at $245.77 on Friday. The firm has a market cap of $29.56 billion, a P/E ratio of 18.86, a P/E/G ratio of 1.71 and a beta of 0.42. The firm’s fifty day moving average is $263.19 and its 200 day moving average is $256.85. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $315.35. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.29. The business had revenue of $32.65 billion during the quarter, compared to analyst estimates of $31.99 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The company’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the business posted $4.16 earnings per share. Research analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.4%. The ex-dividend date is Friday, December 26th. Humana’s dividend payout ratio (DPR) is presently 33.18%.

Wall Street Analyst Weigh In

HUM has been the subject of several recent analyst reports. Wall Street Zen lowered Humana from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Bank of America lifted their target price on shares of Humana from $280.00 to $300.00 and gave the company a “neutral” rating in a research report on Friday, October 10th. Truist Financial decreased their price target on shares of Humana from $300.00 to $285.00 and set a “hold” rating on the stock in a report on Monday, November 10th. Evercore ISI started coverage on shares of Humana in a research report on Monday, September 22nd. They set an “in-line” rating and a $295.00 price objective on the stock. Finally, The Goldman Sachs Group cut their target price on shares of Humana from $235.00 to $215.00 and set a “sell” rating for the company in a research report on Monday, November 24th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average price target of $295.94.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.